4D pharma to Host Virtual KOL Event Discussing Asthma Treatment Landscape and Review of Positive Topline Results from Part A of Phase I/II Trial of MRx-4DP0004
January 20 2022 - 6:00AM
Business Wire
4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical
company leading the development of Live Biotherapeutic products
(LBPs), a novel class of drug derived from the microbiome, today
announced that it will host a virtual Key Opinion Leader (KOL)
event to review previously disclosed positive topline results from
Part A of its Phase I/II trial of MRx-4DP0004 for the treatment of
asthma and to discuss the asthma treatment landscape. The event
will take place on Thursday, January 27, 2022, from 8:00 a.m. ET
(1:00 p.m. GMT).
The event will feature presentations from 4D pharma management
and KOL, Professor Chris Brightling, National Institute for Health
Research (NIHR) Senior Investigator and Clinical Professor in
Respiratory Medicine, Department of Respiratory Sciences,
University of Leicester, UK, and Principle Investigator of the
MRx-4DP0004 Phase I/II trial.
A live webcast of the event will be available on the Reports and
Presentations section of the 4D Pharma website at
www.4dpharmaplc.com. A replay of the webcast and accompanying
slides will be available on the 4D pharma website following the
event.
About 4D pharma
4D pharma is a world leader in the development of Live
Biotherapeutics, a novel and emerging class of drugs, defined by
the FDA as biological products that contain a live organism, such
as a bacterium, that is applicable to the prevention, treatment or
cure of a disease. 4D has developed a proprietary platform,
MicroRx®, that rationally identifies Live Biotherapeutics based on
a deep understanding of function and mechanism. 4D pharma's Live
Biotherapeutic products (LBPs) are orally delivered single strains
of bacteria that are naturally found in the healthy human gut. The
Company has five clinical programs, namely a Phase I/II study of
MRx0518 in combination with KEYTRUDA® (pembrolizumab) in solid
tumors, a Phase I study of MRx0518 in a neoadjuvant setting for
patients with solid tumors, a Phase I study of MRx0518 in patients
with pancreatic cancer, a Phase I/II study of MRx-4DP0004 in
asthma, and Blautix® in Irritable Bowel Syndrome (IBS) which has
completed a successful Phase II trial. Preclinical-stage programs
include candidates for CNS disease such as Parkinson's disease and
other neurodegenerative conditions. The Company has a research
collaboration with MSD, a tradename of Merck & Co., Inc.,
Kenilworth, NJ, USA, to discover and develop Live Biotherapeutics
for vaccines.
For more information, refer to https://www.4dpharmaplc.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220120005125/en/
4D Duncan Peyton, Chief Executive Officer +44 (0)113 895
0130 Investor Relations ir@4dpharmaplc.com
Singer Capital Markets - Nominated Adviser and Joint
Broker +44 (0)20 7496 3000 Philip Davies / James Fischer
(Corporate Finance) Tom Salvesen (Corporate Broking)
Bryan Garnier & Co. Limited - Joint Broker +44 (0)20
7332 2500 Dominic Wilson
Stern Investor Relations Julie Seidel +1-212-362-1200
Julie.seidel@sternir.com
Image Box Communications Neil Hunter / Michelle Boxall
+44 (0)20 8943 4685
6 Degrees Lynne Dardanell +1-336-202-9689
ldardanell@6degreespr.com
4d Pharma (LSE:DDDD)
Historical Stock Chart
From Mar 2024 to Apr 2024
4d Pharma (LSE:DDDD)
Historical Stock Chart
From Apr 2023 to Apr 2024